You just read:

The Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib for Patients with Waldenstrom's Macroglobulinemia

News provided by

The Leukemia & Lymphoma Society

Jan 29, 2015, 03:29 ET